{"id":172421,"date":"2024-03-06T17:00:57","date_gmt":"2024-03-06T14:00:58","guid":{"rendered":"https:\/\/kupitiblog.store\/576r\/gilead-y-merus-firman-un-acuerdo-de-investigacion-de-anticuerpos-triespecificos\/"},"modified":"2024-03-06T17:00:57","modified_gmt":"2024-03-06T14:00:58","slug":"gilead-y-merus-firman-un-acuerdo-de-investigacion-de-anticuerpos-triespecificos","status":"publish","type":"post","link":"https:\/\/kupitiblog.store\/576r\/gilead-y-merus-firman-un-acuerdo-de-investigacion-de-anticuerpos-triespecificos\/","title":{"rendered":"Gilead y Merus firman un acuerdo de investigaci\u00f3n de anticuerpos triespec\u00edficos"},"content":{"rendered":"<p><img decoding=\"async\" src=\"https:\/\/kupitiblog.store\/576r\/wp-content\/uploads\/2024\/03\/1084040de2f91fd85f2b00141f93ce2b.jpg\"  \/> <span class=\"text\"><\/span> <i class=\"imgGrad\"><\/i>    &nbsp;                <\/p>\n<p>FOSTER CITY, California &#8212; Gilead Sciences, Inc. (NASDAQ:<span class=\"aqPopupWrapper js-hover-me-wrapper\">GILD<\/span>) y Merus N.V. (NASDAQ:MRUS) han anunciado un acuerdo de colaboraci\u00f3n para desarrollar nuevas terapias contra el c\u00e1ncer utilizando la tecnolog\u00eda Triclonics\u00ae de Merus. La alianza combinar\u00e1 la experiencia oncol\u00f3gica de Gilead con la plataforma patentada de Merus para investigar y desarrollar anticuerpos triespec\u00edficos dirigidos contra ant\u00edgenos duales asociados a tumores.<\/p>\n<p>Seg\u00fan los t\u00e9rminos del acuerdo, Merus recibir\u00e1 un pago inicial en efectivo de 56 millones de d\u00f3lares y una inversi\u00f3n en capital de 25 millones de d\u00f3lares de Gilead para los objetivos iniciales. Adem\u00e1s, Merus podr\u00e1 recibir hasta 1.500 millones de d\u00f3lares en pagos potenciales, incluidos hitos y regal\u00edas, si Gilead comercializa con \u00e9xito una terapia fruto de la colaboraci\u00f3n. El acuerdo tambi\u00e9n incluye una opci\u00f3n de participaci\u00f3n al 50% en los beneficios y p\u00e9rdidas de un tercer programa potencial, en lugar de pagos futuros.<\/p>\n<p>En el marco de la colaboraci\u00f3n en investigaci\u00f3n, Merus dirigir\u00e1 la investigaci\u00f3n en fase inicial de dos programas, con opci\u00f3n a un tercero. Gilead conservar\u00e1 el derecho de licencia de los programas una vez concluidas determinadas actividades de investigaci\u00f3n, momento en el que asumir\u00e1 las responsabilidades de desarrollo y comercializaci\u00f3n.<\/p>\n<p>El Dr. Flavius Martin, de Gilead, expres\u00f3 su entusiasmo por el potencial de la plataforma Triclonics\u00ae para crear tratamientos transformadores contra el c\u00e1ncer. El Dr. Hui Liu, de Merus, destac\u00f3 la colaboraci\u00f3n como una oportunidad de aprovechar sus capacidades de investigaci\u00f3n para abordar importantes necesidades m\u00e9dicas no cubiertas y como la primera para su plataforma patentada Triclonics\u00ae.<\/p>\n<p>Se espera que el impacto financiero de la transacci\u00f3n reduzca el BPA GAAP y no GAAP 2024 de Gilead en aproximadamente 0,03 &#8212; 0,05 d\u00f3lares. Ambas compa\u00f1\u00edas han realizado declaraciones prospectivas sobre los beneficios potenciales de la colaboraci\u00f3n y el \u00e9xito del desarrollo de los programas.<\/p>\n<p>Merus es conocida por el desarrollo de Multiclonics\u00ae, innovadores anticuerpos biespec\u00edficos y triespec\u00edficos humanos de longitud completa, mientras que Gilead Sciences es una compa\u00f1\u00eda biofarmac\u00e9utica centrada en enfermedades potencialmente mortales, como el VIH, la hepatitis v\u00edrica, la COVID-19 y el c\u00e1ncer.<\/p>\n<p>Esta noticia se basa en un comunicado de prensa.<\/p>\n<\/p>\n<p><a target=\"_blank\" rel=\"nofollow noopener\" href=\"http:\/\/es.investing.com\/news\/stock-market-news\/gilead-y-merus-firman-un-acuerdo-de-investigacion-de-anticuerpos-triespecificos-93CH-2593802\">Fuente<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&nbsp; FOSTER CITY, California &#8212; Gilead Sciences, Inc. (NASDAQ:GILD) y Merus N.V. (NASDAQ:MRUS) han anunciado un acuerdo de colaboraci\u00f3n para desarrollar nuevas terapias contra el c\u00e1ncer utilizando la tecnolog\u00eda Triclonics\u00ae de Merus. La alianza combinar\u00e1 la experiencia oncol\u00f3gica de Gilead con la plataforma patentada de Merus para investigar y desarrollar anticuerpos triespec\u00edficos dirigidos contra ant\u00edgenos &hellip;<\/p>\n","protected":false},"author":1,"featured_media":172881,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3360],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v16.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Gilead y Merus firman un acuerdo de investigaci\u00f3n de anticuerpos triespec\u00edficos - BiznesSMI - \u043a\u043e\u0442\u0438\u0440\u043e\u0432\u043a\u0438 \u0432\u0430\u043b\u044e\u0442, \u0430\u043a\u0446\u0438\u0438, \u0444\u043e\u0440\u0435\u043a\u0441, \u0438\u043d\u0434\u0435\u043a\u0441\u044b, \u0430 \u0442\u0430\u043a\u0436\u0435 \u0442\u0435\u0445\u043d\u0438\u0447\u0435\u0441\u043a\u0438\u0439 \u0430\u043d\u0430\u043b\u0438\u0437, \u0433\u0440\u0430\u0444\u0438\u043a\u0438, \u0444\u0438\u043d\u0430\u043d\u0441\u043e\u0432\u044b\u0435 \u043d\u043e\u0432\u043e\u0441\u0442\u0438 \u0438 \u0430\u043d\u0430\u043b\u0438\u0442\u0438\u043a\u0430.<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"ru_RU\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gilead y Merus firman un acuerdo de investigaci\u00f3n de anticuerpos triespec\u00edficos - BiznesSMI - \u043a\u043e\u0442\u0438\u0440\u043e\u0432\u043a\u0438 \u0432\u0430\u043b\u044e\u0442, \u0430\u043a\u0446\u0438\u0438, \u0444\u043e\u0440\u0435\u043a\u0441, \u0438\u043d\u0434\u0435\u043a\u0441\u044b, \u0430 \u0442\u0430\u043a\u0436\u0435 \u0442\u0435\u0445\u043d\u0438\u0447\u0435\u0441\u043a\u0438\u0439 \u0430\u043d\u0430\u043b\u0438\u0437, \u0433\u0440\u0430\u0444\u0438\u043a\u0438, \u0444\u0438\u043d\u0430\u043d\u0441\u043e\u0432\u044b\u0435 \u043d\u043e\u0432\u043e\u0441\u0442\u0438 \u0438 \u0430\u043d\u0430\u043b\u0438\u0442\u0438\u043a\u0430.\" \/>\n<meta property=\"og:description\" content=\"&nbsp; FOSTER CITY, California &#8212; Gilead Sciences, Inc. (NASDAQ:GILD) y Merus N.V. (NASDAQ:MRUS) han anunciado un acuerdo de colaboraci\u00f3n para desarrollar nuevas terapias contra el c\u00e1ncer utilizando la tecnolog\u00eda Triclonics\u00ae de Merus. La alianza combinar\u00e1 la experiencia oncol\u00f3gica de Gilead con la plataforma patentada de Merus para investigar y desarrollar anticuerpos triespec\u00edficos dirigidos contra ant\u00edgenos &hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kupitiblog.store\/576r\/gilead-y-merus-firman-un-acuerdo-de-investigacion-de-anticuerpos-triespecificos\/\" \/>\n<meta property=\"og:site_name\" content=\"BiznesSMI - \u043a\u043e\u0442\u0438\u0440\u043e\u0432\u043a\u0438 \u0432\u0430\u043b\u044e\u0442, \u0430\u043a\u0446\u0438\u0438, \u0444\u043e\u0440\u0435\u043a\u0441, \u0438\u043d\u0434\u0435\u043a\u0441\u044b, \u0430 \u0442\u0430\u043a\u0436\u0435 \u0442\u0435\u0445\u043d\u0438\u0447\u0435\u0441\u043a\u0438\u0439 \u0430\u043d\u0430\u043b\u0438\u0437, \u0433\u0440\u0430\u0444\u0438\u043a\u0438, \u0444\u0438\u043d\u0430\u043d\u0441\u043e\u0432\u044b\u0435 \u043d\u043e\u0432\u043e\u0441\u0442\u0438 \u0438 \u0430\u043d\u0430\u043b\u0438\u0442\u0438\u043a\u0430.\" \/>\n<meta property=\"article:published_time\" content=\"2024-03-06T14:00:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kupitiblog.store\/576r\/wp-content\/uploads\/2024\/03\/1084040de2f91fd85f2b00141f93ce2b.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u041f\u0440\u0438\u043c\u0435\u0440\u043d\u043e\u0435 \u0432\u0440\u0435\u043c\u044f \u0434\u043b\u044f \u0447\u0442\u0435\u043d\u0438\u044f\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 \u043c\u0438\u043d\u0443\u0442\u044b\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebSite\",\"@id\":\"https:\/\/kupitiblog.store\/576r\/#website\",\"url\":\"https:\/\/kupitiblog.store\/576r\/\",\"name\":\"BiznesSMI - \\u043a\\u043e\\u0442\\u0438\\u0440\\u043e\\u0432\\u043a\\u0438 \\u0432\\u0430\\u043b\\u044e\\u0442, \\u0430\\u043a\\u0446\\u0438\\u0438, \\u0444\\u043e\\u0440\\u0435\\u043a\\u0441, \\u0438\\u043d\\u0434\\u0435\\u043a\\u0441\\u044b, \\u0430 \\u0442\\u0430\\u043a\\u0436\\u0435 \\u0442\\u0435\\u0445\\u043d\\u0438\\u0447\\u0435\\u0441\\u043a\\u0438\\u0439 \\u0430\\u043d\\u0430\\u043b\\u0438\\u0437, \\u0433\\u0440\\u0430\\u0444\\u0438\\u043a\\u0438, \\u0444\\u0438\\u043d\\u0430\\u043d\\u0441\\u043e\\u0432\\u044b\\u0435 \\u043d\\u043e\\u0432\\u043e\\u0441\\u0442\\u0438 \\u0438 \\u0430\\u043d\\u0430\\u043b\\u0438\\u0442\\u0438\\u043a\\u0430.\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":\"https:\/\/kupitiblog.store\/576r\/?s={search_term_string}\",\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"ru-RU\"},{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/kupitiblog.store\/576r\/gilead-y-merus-firman-un-acuerdo-de-investigacion-de-anticuerpos-triespecificos\/#primaryimage\",\"inLanguage\":\"ru-RU\",\"url\":\"https:\/\/kupitiblog.store\/576r\/wp-content\/uploads\/2024\/03\/1084040de2f91fd85f2b00141f93ce2b-1.jpg\",\"contentUrl\":\"https:\/\/kupitiblog.store\/576r\/wp-content\/uploads\/2024\/03\/1084040de2f91fd85f2b00141f93ce2b-1.jpg\",\"width\":800,\"height\":533},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/kupitiblog.store\/576r\/gilead-y-merus-firman-un-acuerdo-de-investigacion-de-anticuerpos-triespecificos\/#webpage\",\"url\":\"https:\/\/kupitiblog.store\/576r\/gilead-y-merus-firman-un-acuerdo-de-investigacion-de-anticuerpos-triespecificos\/\",\"name\":\"Gilead y Merus firman un acuerdo de investigaci\\u00f3n de anticuerpos triespec\\u00edficos - BiznesSMI - \\u043a\\u043e\\u0442\\u0438\\u0440\\u043e\\u0432\\u043a\\u0438 \\u0432\\u0430\\u043b\\u044e\\u0442, \\u0430\\u043a\\u0446\\u0438\\u0438, \\u0444\\u043e\\u0440\\u0435\\u043a\\u0441, \\u0438\\u043d\\u0434\\u0435\\u043a\\u0441\\u044b, \\u0430 \\u0442\\u0430\\u043a\\u0436\\u0435 \\u0442\\u0435\\u0445\\u043d\\u0438\\u0447\\u0435\\u0441\\u043a\\u0438\\u0439 \\u0430\\u043d\\u0430\\u043b\\u0438\\u0437, \\u0433\\u0440\\u0430\\u0444\\u0438\\u043a\\u0438, \\u0444\\u0438\\u043d\\u0430\\u043d\\u0441\\u043e\\u0432\\u044b\\u0435 \\u043d\\u043e\\u0432\\u043e\\u0441\\u0442\\u0438 \\u0438 \\u0430\\u043d\\u0430\\u043b\\u0438\\u0442\\u0438\\u043a\\u0430.\",\"isPartOf\":{\"@id\":\"https:\/\/kupitiblog.store\/576r\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/kupitiblog.store\/576r\/gilead-y-merus-firman-un-acuerdo-de-investigacion-de-anticuerpos-triespecificos\/#primaryimage\"},\"datePublished\":\"2024-03-06T14:00:58+00:00\",\"dateModified\":\"2024-03-06T14:00:58+00:00\",\"author\":{\"@id\":\"https:\/\/kupitiblog.store\/576r\/#\/schema\/person\/5d8353a37f91122aa6e3893c3f66436a\"},\"breadcrumb\":{\"@id\":\"https:\/\/kupitiblog.store\/576r\/gilead-y-merus-firman-un-acuerdo-de-investigacion-de-anticuerpos-triespecificos\/#breadcrumb\"},\"inLanguage\":\"ru-RU\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/kupitiblog.store\/576r\/gilead-y-merus-firman-un-acuerdo-de-investigacion-de-anticuerpos-triespecificos\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/kupitiblog.store\/576r\/gilead-y-merus-firman-un-acuerdo-de-investigacion-de-anticuerpos-triespecificos\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\\u0413\\u043b\\u0430\\u0432\\u043d\\u0430\\u044f \\u0441\\u0442\\u0440\\u0430\\u043d\\u0438\\u0446\\u0430\",\"item\":\"https:\/\/kupitiblog.store\/576r\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gilead y Merus firman un acuerdo de investigaci\\u00f3n de anticuerpos triespec\\u00edficos\"}]},{\"@type\":\"Person\",\"@id\":\"https:\/\/kupitiblog.store\/576r\/#\/schema\/person\/5d8353a37f91122aa6e3893c3f66436a\",\"name\":\"Admin\",\"url\":\"https:\/\/kupitiblog.store\/576r\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","_links":{"self":[{"href":"https:\/\/kupitiblog.store\/576r\/wp-json\/wp\/v2\/posts\/172421"}],"collection":[{"href":"https:\/\/kupitiblog.store\/576r\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kupitiblog.store\/576r\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kupitiblog.store\/576r\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kupitiblog.store\/576r\/wp-json\/wp\/v2\/comments?post=172421"}],"version-history":[{"count":0,"href":"https:\/\/kupitiblog.store\/576r\/wp-json\/wp\/v2\/posts\/172421\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kupitiblog.store\/576r\/wp-json\/wp\/v2\/media\/172881"}],"wp:attachment":[{"href":"https:\/\/kupitiblog.store\/576r\/wp-json\/wp\/v2\/media?parent=172421"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kupitiblog.store\/576r\/wp-json\/wp\/v2\/categories?post=172421"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kupitiblog.store\/576r\/wp-json\/wp\/v2\/tags?post=172421"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}